{
  "id": "map_1881",
  "title": "SÍNDROMES NEUROPSIQUIÁTRICOS (NPS) EN TRASTORNOS NEURODEGENERATIVOS (NDD)\\N(Review JAMA Neurol 2024)",
  "specialty": "Neurología",
  "tag": "⭐ Estudio Pivotal",
  "node_count": 410,
  "root": {
    "text": "SÍNDROMES NEUROPSIQUIÁTRICOS (NPS) EN TRASTORNOS NEURODEGENERATIVOS (NDD)\\N(Review JAMA Neurol 2024)",
    "children": [
      {
        "text": "IMPORTANCIA",
        "children": [
          {
            "text": "↓ calidad vida (pacientes + cuidadores)",
            "children": []
          },
          {
            "text": "↑ progresión enfermedad",
            "children": []
          },
          {
            "text": "↑ necesidad atención residencia",
            "children": []
          },
          {
            "text": "↓ calidad vida",
            "children": []
          },
          {
            "text": "→ comunes todos NDD",
            "children": [
              {
                "text": "• Incluidos criterios diagnósticos (2)",
                "children": []
              },
              {
                "text": "• AD: casi 100% pacientes fase demencia",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "IMPACTO\\NNPS EN AD",
        "children": [
          {
            "text": "↑ deterioro cognitivo",
            "children": []
          },
          {
            "text": "↑ deterioro funcional",
            "children": []
          },
          {
            "text": "↓ calidad vida",
            "children": []
          },
          {
            "text": "↑ institucionalización",
            "children": []
          },
          {
            "text": "↑ angustia cuidador ",
            "children": []
          }
        ]
      },
      {
        "text": "INTERVENCIONES NO\\NFARMACOLÓGICAS",
        "children": [
          {
            "text": "• Modificación ambiental",
            "children": []
          },
          {
            "text": "• Programas actividad/ejercicio",
            "children": []
          },
          {
            "text": "• Música",
            "children": []
          },
          {
            "text": "• Toque terapéutico\\N(masaje/acupresión)",
            "children": []
          },
          {
            "text": "• Terapia asistida animales",
            "children": []
          },
          {
            "text": "• Actividades combinadas",
            "children": []
          },
          {
            "text": "• Desprescripción\\Nmedicación agitadora",
            "children": []
          }
        ]
      },
      {
        "text": "CRITERIOS\\NNPS",
        "children": [
          {
            "text": "• Desarrollo criterios\\Ndiagnósticos:",
            "children": [
              {
                "text": "→ NDD manifestados",
                "children": []
              },
              {
                "text": "→ estados prodrómicos",
                "children": []
              }
            ]
          },
          {
            "text": "• Beneficios:",
            "children": [
              {
                "text": "→ mejor diseño ensayos clínicos",
                "children": []
              },
              {
                "text": "→ ayuda identificación pacientes tratamiento",
                "children": []
              }
            ]
          },
          {
            "text": "PRINCIPALES NPS",
            "children": [
              {
                "text": "1. Psicosis",
                "children": []
              },
              {
                "text": "2. Agitación",
                "children": []
              },
              {
                "text": "3. Depresión",
                "children": []
              },
              {
                "text": "4. Apatía",
                "children": []
              },
              {
                "text": "5. Desinhibición",
                "children": []
              }
            ]
          },
          {
            "text": "OTROS NPS\\NRELEVANTES",
            "children": [
              {
                "text": "• Alteraciones sueño",
                "children": []
              },
              {
                "text": "• Ansiedad",
                "children": []
              },
              {
                "text": "• Irritabilidad",
                "children": []
              },
              {
                "text": "• Alteraciones conducta sexual",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "CRITERIOS\\NDIAGNÓSTICOS NPS EN\\NNDD",
        "children": [
          {
            "text": "1. AGITACIÓN EN\\NDETERIORO COGNITIVO",
            "children": [
              {
                "text": "Últimas 2 semanas:",
                "children": [
                  {
                    "text": "• Actividad motora excesiva",
                    "children": []
                  },
                  {
                    "text": "• Agresión verbal",
                    "children": []
                  },
                  {
                    "text": "• Agresión física",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "2. PSICOSIS",
            "children": [
              {
                "text": "A. Deterioro neurocognitivo mayor/leve (21)",
                "children": [
                  {
                    "text": "≥1 síntoma, intermitente,\\N≥1 mes:",
                    "children": [
                      {
                        "text": "• Alucinaciones visuales/auditivas",
                        "children": []
                      },
                      {
                        "text": "• Delusiones",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "B. Parkinson (25)",
                "children": [
                  {
                    "text": "≥1 síntoma, continuo/recurrente,\\Núltimo mes:",
                    "children": [
                      {
                        "text": "• Ilusiones",
                        "children": []
                      },
                      {
                        "text": "• Falsa sensación presencia",
                        "children": []
                      },
                      {
                        "text": "• Alucinaciones",
                        "children": []
                      },
                      {
                        "text": "• Delusiones",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "3. APATÍA EN TRASTORNOS\\NNEUROCOGNITIVOS (23)",
            "children": [
              {
                "text": "≥1 dimensión\\Nsintomática, ≥1 mes:",
                "children": [
                  {
                    "text": "• ↓ iniciativa",
                    "children": []
                  },
                  {
                    "text": "• ↓ interés",
                    "children": []
                  },
                  {
                    "text": "• ↓ expresividad/respuesta emocional",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "4. DEPRESIÓN",
            "children": [
              {
                "text": "A. Alzheimer (26)",
                "children": [
                  {
                    "text": "≥3 síntomas, 2\\Nsemanas:",
                    "children": [
                      {
                        "text": "• Ánimo deprimido",
                        "children": []
                      },
                      {
                        "text": "• ↓ afecto positivo/placer",
                        "children": []
                      },
                      {
                        "text": "• Alteración apetito",
                        "children": []
                      },
                      {
                        "text": "• Alteración sueño",
                        "children": []
                      },
                      {
                        "text": "• Cambios psicomotores",
                        "children": []
                      },
                      {
                        "text": "• Fatiga/↓ energía",
                        "children": []
                      },
                      {
                        "text": "• Sentimientos inutilidad/desesperanza/culpa",
                        "children": []
                      },
                      {
                        "text": "• ↓ capacidad pensamiento/concentración",
                        "children": []
                      },
                      {
                        "text": "• Ideas muerte/suicidio",
                        "children": []
                      },
                      {
                        "text": "• Aislamiento social",
                        "children": []
                      },
                      {
                        "text": "• Irritabilidad",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "B. Parkinson (27)",
                "children": [
                  {
                    "text": "≥5 síntomas, 2\\Nsemanas:",
                    "children": [
                      {
                        "text": "• Ánimo deprimido",
                        "children": []
                      },
                      {
                        "text": "• ↓ interés/placer",
                        "children": []
                      },
                      {
                        "text": "• Alteración peso/apetito",
                        "children": []
                      },
                      {
                        "text": "• Insomnio/hipersomnia",
                        "children": []
                      },
                      {
                        "text": "• Agitación/retardo psicomotor",
                        "children": []
                      },
                      {
                        "text": "• Fatiga/↓ energía",
                        "children": []
                      },
                      {
                        "text": "• Sentimientos inutilidad/culpa",
                        "children": []
                      },
                      {
                        "text": "• ↓ capacidad pensamiento/concentración/indecisión",
                        "children": []
                      },
                      {
                        "text": "• Ideas muerte/suicidio",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "5. DESINHIBICIÓN\\NEN NDD",
            "children": [
              {
                "text": "• Conducta social inapropiada",
                "children": []
              },
              {
                "text": "• Pérdida modales/decoro",
                "children": []
              },
              {
                "text": "• Acciones impulsivas/precipitadas",
                "children": []
              }
            ]
          },
          {
            "text": "6. SÍNDROME ENCEFALOPATÍA\\NTRAUMÁTICA (24)",
            "children": [
              {
                "text": "• Explosividad",
                "children": []
              },
              {
                "text": "• Impulsividad",
                "children": []
              },
              {
                "text": "• Descontrol emocional",
                "children": []
              },
              {
                "text": "• Labilidad afectiva",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "PRÁCTICA\\NCLÍNICA ÓPTIMA",
        "children": [
          {
            "text": "1. Diagnóstico NDD",
            "children": [
              {
                "text": "→ uso biomarcadores (si disponibles)",
                "children": []
              }
            ]
          },
          {
            "text": "2. Identificación NPS dominante",
            "children": []
          },
          {
            "text": "3. Tratamiento:",
            "children": [
              {
                "text": "→ psicosocial",
                "children": []
              },
              {
                "text": "→ farmacológico (según necesidad)",
                "children": []
              }
            ]
          },
          {
            "text": "4. Vigilancia síntomas\\Nneuropsiquiátricos inducidos fármacos",
            "children": [
              {
                "text": "→ ej: trastornos control impulsos +\\Nagonistas dopamina en PD (29)",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "PSICOSIS EN NDD",
        "children": [
          {
            "text": "CRITERIOS\\NDIAGNÓSTICOS",
            "children": [
              {
                "text": "• Criterios\\Nconsenso IPA:",
                "children": [
                  {
                    "text": "→ base: criterios Jeste-Finkel (30)",
                    "children": []
                  },
                  {
                    "text": "→ requiere: alucinaciones/delusiones",
                    "children": []
                  },
                  {
                    "text": "→ duración: ≥1 mes",
                    "children": []
                  },
                  {
                    "text": "→ excluye: delirium/psicosis previa",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "MANIFESTACIONES\\NCLÍNICAS",
            "children": [
              {
                "text": "1. Delusiones comunes",
                "children": [
                  {
                    "text": "• Robo",
                    "children": []
                  },
                  {
                    "text": "• Daño",
                    "children": []
                  },
                  {
                    "text": "• Infidelidad",
                    "children": []
                  },
                  {
                    "text": "• Abandono",
                    "children": []
                  },
                  {
                    "text": "• Delusiones sistematizadas raras",
                    "children": []
                  }
                ]
              },
              {
                "text": "2. Alucinaciones",
                "children": [
                  {
                    "text": "• Visuales: personas/animales",
                    "children": []
                  },
                  {
                    "text": "• Auditivas: voces",
                    "children": []
                  }
                ]
              },
              {
                "text": "3. Síndromes\\Nmisidentificación",
                "children": [
                  {
                    "text": "• Síndrome huésped fantasma",
                    "children": []
                  },
                  {
                    "text": "• Síndrome Capgras",
                    "children": []
                  },
                  {
                    "text": "• Signo TV",
                    "children": []
                  },
                  {
                    "text": "• No reconocimiento espejo",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "FRECUENCIA",
            "children": [
              {
                "text": "• AD:",
                "children": [
                  {
                    "text": "→ delusiones 30%",
                    "children": []
                  },
                  {
                    "text": "→ alucinaciones 20%",
                    "children": []
                  }
                ]
              },
              {
                "text": "• DLB: alucinaciones visuales 75%",
                "children": []
              },
              {
                "text": "• PD demencia: alucinaciones visuales 50%",
                "children": []
              },
              {
                "text": "• FTD: síntomas psicóticos 10%",
                "children": []
              }
            ]
          },
          {
            "text": "FARMACOTERAPIA",
            "children": [
              {
                "text": "1. Pimavanserin",
                "children": [
                  {
                    "text": "• Único antipsicótico aprobado NDD",
                    "children": []
                  },
                  {
                    "text": "• Indicación: psicosis en PD ± demencia",
                    "children": []
                  },
                  {
                    "text": "• Mecanismo: agonista inverso selectivo 5-HT2A (38)",
                    "children": []
                  }
                ]
              },
              {
                "text": "2. Antipsicóticos\\Natípicos",
                "children": [
                  {
                    "text": "• Eficacia modesta",
                    "children": [
                      {
                        "text": "• Aripiprazol",
                        "children": []
                      },
                      {
                        "text": "• Risperidona",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "• Riesgos:",
                    "children": [
                      {
                        "text": "→ ictus",
                        "children": []
                      },
                      {
                        "text": "→ caídas",
                        "children": []
                      },
                      {
                        "text": "→ ↑ deterioro cognitivo",
                        "children": []
                      },
                      {
                        "text": "→ ↑ mortalidad (41)",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "3. Otros\\Nfármacos",
                "children": [
                  {
                    "text": "• Inhibidores\\Ncolinesterasa:",
                    "children": [
                      {
                        "text": "→ eficaces DLB",
                        "children": []
                      },
                      {
                        "text": "→ eficacia moderada AD",
                        "children": []
                      },
                      {
                        "text": "→ eficacia dudosa PD demencia",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "• Memantina: eficacia limitada",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "AGITACIÓN EN NDD",
        "children": [
          {
            "text": "CARACTERÍSTICAS",
            "children": [
              {
                "text": "• NPS más común/problemático (22)",
                "children": []
              },
              {
                "text": "• Manifestaciones:",
                "children": [
                  {
                    "text": "→ golpes",
                    "children": []
                  },
                  {
                    "text": "→ empujones",
                    "children": []
                  },
                  {
                    "text": "→ patadas",
                    "children": []
                  },
                  {
                    "text": "→ gritos",
                    "children": []
                  },
                  {
                    "text": "→ resistencia cuidados",
                    "children": []
                  }
                ]
              },
              {
                "text": "• Precedido/acompañado irritabilidad (44)",
                "children": []
              }
            ]
          },
          {
            "text": "IMPACTO EN AD",
            "children": [
              {
                "text": "↑ progresión enfermedad",
                "children": []
              },
              {
                "text": "↑ mortalidad temprana (45)",
                "children": []
              },
              {
                "text": "↑ hospitalizaciones (46)",
                "children": []
              },
              {
                "text": "↑ institucionalización precoz (47)",
                "children": []
              },
              {
                "text": "↓ calidad vida (pacientes + familias)",
                "children": []
              }
            ]
          },
          {
            "text": "PREVALENCIA AD",
            "children": [
              {
                "text": "• 60% pacientes",
                "children": []
              },
              {
                "text": "• Cualquier estadio",
                "children": []
              },
              {
                "text": "• Frecuencia/severidad ↑:",
                "children": [
                  {
                    "text": "→ progresión enfermedad",
                    "children": []
                  },
                  {
                    "text": "→ deterioro cognitivo (48,49)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "MANEJO CLÍNICO",
            "children": [
              {
                "text": "1. ALGORITMOS\\NDIAGNÓSTICO DIFERENCIAL",
                "children": [
                  {
                    "text": "• Delirium",
                    "children": []
                  },
                  {
                    "text": "• Dolor/malestar",
                    "children": []
                  },
                  {
                    "text": "• Depresión",
                    "children": []
                  },
                  {
                    "text": "• Psicosis",
                    "children": []
                  },
                  {
                    "text": "• Estresores ambientales/psicosociales (14,15)",
                    "children": []
                  }
                ]
              },
              {
                "text": "2. FARMACOTERAPIA",
                "children": [
                  {
                    "text": "A. Brexpiprazol",
                    "children": [
                      {
                        "text": "• 1º fármaco aprobado FDA",
                        "children": []
                      },
                      {
                        "text": "• Dosis: 2-3mg/d",
                        "children": []
                      },
                      {
                        "text": "• Titulación: 0. 5→1-2mg/d (2 semanas)",
                        "children": []
                      },
                      {
                        "text": "• Advertencia: no indicado psicosis-demencia (52-54)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "B. Antipsicóticos\\Natípicos",
                    "children": [
                      {
                        "text": "• Quetiapina",
                        "children": []
                      },
                      {
                        "text": "• Olanzapina",
                        "children": []
                      },
                      {
                        "text": "• Aripiprazol",
                        "children": []
                      },
                      {
                        "text": "• Risperidona",
                        "children": []
                      },
                      {
                        "text": "• Quetiapina",
                        "children": []
                      },
                      {
                        "text": "• Uso: síntomas severos/peligrosos (55)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "C. Otros",
                    "children": [
                      {
                        "text": "• Benzodiazepinas: NO recomendadas (56)",
                        "children": []
                      },
                      {
                        "text": "• Citalopram:",
                        "children": [
                          {
                            "text": "→ eficaz 30mg/d",
                            "children": []
                          },
                          {
                            "text": "→ riesgo QTc >20mg/d (57)",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "• Escitalopram: en estudio (58)",
                        "children": []
                      },
                      {
                        "text": "• Carbamazepina",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "3. APATÍA",
        "children": [
          {
            "text": "A. Estimulantes",
            "children": [
              {
                "text": "• Metilfenidato",
                "children": []
              },
              {
                "text": "• Modafinil",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "5. DESINHIBICIÓN",
        "children": [
          {
            "text": "• Citalopram:\\Nensayo abierto",
            "children": []
          },
          {
            "text": "• Ácido valproico:\\Ncasos reportados",
            "children": []
          },
          {
            "text": "• Metilfenidato: ensayo\\Ncruzado controlado",
            "children": []
          },
          {
            "text": "• Dextrometorfano +\\Nquinidina: casos reportados",
            "children": []
          }
        ]
      },
      {
        "text": "NOTAS:",
        "children": [
          {
            "text": "• Dosis: individualizar según\\Nindicaciones aprobadas",
            "children": []
          },
          {
            "text": "• Revisar efectos adversos\\Nantes prescripción",
            "children": []
          },
          {
            "text": "• No incluidos fármacos con\\Nensayos negativos",
            "children": []
          }
        ]
      },
      {
        "text": "DEPRESIÓN EN NDD",
        "children": [
          {
            "text": "EPIDEMIOLOGÍA",
            "children": [
              {
                "text": "• AD: 40% durante evolución (60)",
                "children": []
              },
              {
                "text": "• Trastornos cuerpos Lewy: hasta 80%",
                "children": []
              },
              {
                "text": "→ PD",
                "children": []
              },
              {
                "text": "→ DLB",
                "children": []
              },
              {
                "text": "→ atrofia multisistémica (62)",
                "children": []
              }
            ]
          },
          {
            "text": "IMPACTO EN AD",
            "children": [
              {
                "text": "Sin diagnóstico/tratamiento\\N→",
                "children": [
                  {
                    "text": "• ↑ deterioro cognitivo",
                    "children": []
                  },
                  {
                    "text": "• ↑ mortalidad",
                    "children": []
                  },
                  {
                    "text": "• ↑ riesgo suicidio (60)",
                    "children": []
                  },
                  {
                    "text": "• Posible marcador temprano/factor riesgo AD (61)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "DESAFÍOS\\NDIAGNÓSTICOS",
            "children": [
              {
                "text": "1. Enmascaramiento:",
                "children": [
                  {
                    "text": "• Comorbilidades médicas",
                    "children": []
                  },
                  {
                    "text": "• Solapamiento\\Nsíntomas:",
                    "children": [
                      {
                        "text": "→ demencia",
                        "children": []
                      },
                      {
                        "text": "→ apatía",
                        "children": []
                      },
                      {
                        "text": "→ ↓ actividad cognitiva",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "2. Dificultades\\Nexpresión:",
                "children": [
                  {
                    "text": "• Deterioro cognitivo",
                    "children": []
                  },
                  {
                    "text": "• ↓ autoconciencia",
                    "children": []
                  }
                ]
              },
              {
                "text": "3. Claves\\Ndiagnósticas AD:",
                "children": [
                  {
                    "text": "• Progresión súbita inexplicada",
                    "children": []
                  },
                  {
                    "text": "• Pérdida peso",
                    "children": []
                  },
                  {
                    "text": "• Alteración sueño",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "EVALUACIÓN",
            "children": [
              {
                "text": "• Cuestionario Salud Paciente-9 ítems (63)",
                "children": []
              },
              {
                "text": "• Entrevista clínica + información familia/cuidadores (64)",
                "children": []
              }
            ]
          },
          {
            "text": "TRATAMIENTO",
            "children": [
              {
                "text": "1. Plan\\Nbiopsicosocial-ambiental:",
                "children": [
                  {
                    "text": "• Abordaje estresores psicológicos/ambientales",
                    "children": []
                  },
                  {
                    "text": "• Psicoterapia:",
                    "children": [
                      {
                        "text": "→ terapia cognitivo-conductual",
                        "children": []
                      },
                      {
                        "text": "→ terapia interpersonal",
                        "children": []
                      },
                      {
                        "text": "→ counseling",
                        "children": []
                      },
                      {
                        "text": "→ intervenciones multimodales (65,66)",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "2. Farmacoterapia:",
                "children": [
                  {
                    "text": "• Sin fármacos aprobados FDA",
                    "children": []
                  },
                  {
                    "text": "• Pocos ensayos controlados",
                    "children": []
                  },
                  {
                    "text": "• Opciones basadas\\Nexperiencia:",
                    "children": [
                      {
                        "text": "A. ISRS (PD)",
                        "children": [
                          {
                            "text": "• Paroxetina",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "B. IRSN (PD)",
                        "children": [
                          {
                            "text": "• Venlafaxina",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "C. Otros",
                        "children": [
                          {
                            "text": "• Vortioxetina: ensayo abierto",
                            "children": []
                          },
                          {
                            "text": "• Pramipexol (PD): ensayos controlados",
                            "children": []
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "text": "• Posible resistencia tratamiento + carga amiloide cerebral ↑ (67)",
                    "children": []
                  }
                ]
              },
              {
                "text": "3. Casos severos/psicóticos/amenaza vital:",
                "children": [
                  {
                    "text": "• TEC: segura/eficaz (68)",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "APATÍA EN NDD",
        "children": [
          {
            "text": "PREVALENCIA\\NSEGÚN NDD (69)",
            "children": [
              {
                "text": "• AD: 24-85%",
                "children": []
              },
              {
                "text": "• FTD: 50-100%",
                "children": []
              },
              {
                "text": "• HD: 52-76%",
                "children": []
              },
              {
                "text": "• PSP: 20-92%",
                "children": []
              },
              {
                "text": "• PD: 17-70%",
                "children": []
              },
              {
                "text": "• DLB: 35-100%",
                "children": []
              },
              {
                "text": "• Demencia vascular: 43-89%",
                "children": []
              }
            ]
          },
          {
            "text": "IMPACTO",
            "children": [
              {
                "text": "• Deterioro cognitivo leve → demencia: riesgo ×2 (70)",
                "children": []
              },
              {
                "text": "• Mortalidad corto plazo: riesgo ×3 (71)",
                "children": []
              },
              {
                "text": "• Otros efectos:",
                "children": [
                  {
                    "text": "→ ↑ angustia cuidador",
                    "children": []
                  },
                  {
                    "text": "→ ↑ riesgo fragilidad",
                    "children": []
                  },
                  {
                    "text": "→ ↑ costes cuidados",
                    "children": []
                  },
                  {
                    "text": "→ ↓ respuesta tratamientos (70,72)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "NEUROBIOLOGÍA",
            "children": [
              {
                "text": "1. Disfunción circuitos fronto-subcorticales (73)",
                "children": []
              },
              {
                "text": "2. Alteraciones\\Nestructurales",
                "children": [
                  {
                    "text": "• ↓ sustancia gris frontal/prefrontal medial",
                    "children": []
                  },
                  {
                    "text": "• ↓ sustancia blanca frontal",
                    "children": []
                  },
                  {
                    "text": "• ↑ hiperintensidades sustancia blanca frontal (74)",
                    "children": []
                  }
                ]
              },
              {
                "text": "3. Alteraciones funcionales AD\\N+ apatía",
                "children": [
                  {
                    "text": "• ↓ actividad metabólica\\N(PET-FDG):",
                    "children": [
                      {
                        "text": "→ cíngulo anterior",
                        "children": []
                      },
                      {
                        "text": "→ región orbitofrontal medial",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "• Correlación:",
                    "children": [
                      {
                        "text": "→ ovillos neurofibrilares frontales",
                        "children": []
                      },
                      {
                        "text": "→ depósito amiloide (variable) (74)",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "TRATAMIENTO",
            "children": [
              {
                "text": "1. No farmacológico",
                "children": [
                  {
                    "text": "• Intervenciones psicosociales",
                    "children": []
                  },
                  {
                    "text": "• Música",
                    "children": []
                  },
                  {
                    "text": "• Actividad física (69,75)",
                    "children": []
                  },
                  {
                    "text": "• Estimulación cerebral\\Nno invasiva:",
                    "children": [
                      {
                        "text": "→ estimulación transcraneal directa",
                        "children": []
                      },
                      {
                        "text": "→ estimulación magnética transcraneal repetitiva (69,72)",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "2. Farmacológico",
                "children": [
                  {
                    "text": "• Metilfenidato: resultados positivos AD (76,77)",
                    "children": []
                  },
                  {
                    "text": "• Modafinilo: resultados inconsistentes (69,72)",
                    "children": []
                  },
                  {
                    "text": "• Inhibidores colinesterasa: beneficio modesto (78)",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "DESINHIBICIÓN\\NEN NDD",
        "children": [
          {
            "text": "CARACTERÍSTICAS\\NCLÍNICAS (28)",
            "children": [
              {
                "text": "1. Conductas socialmente\\Ninapropiadas:",
                "children": [
                  {
                    "text": "• Acercamiento/contacto extraños",
                    "children": []
                  },
                  {
                    "text": "• Actos sexuales impropios",
                    "children": []
                  }
                ]
              },
              {
                "text": "2. Pérdida\\Ndecoro:",
                "children": [
                  {
                    "text": "• Risa inapropiada",
                    "children": []
                  },
                  {
                    "text": "• Maldiciones",
                    "children": []
                  },
                  {
                    "text": "• Voz alta",
                    "children": []
                  },
                  {
                    "text": "• Bromas ofensivas",
                    "children": []
                  },
                  {
                    "text": "• Comentarios sexuales explícitos",
                    "children": []
                  },
                  {
                    "text": "• Revelación información personal",
                    "children": []
                  }
                ]
              },
              {
                "text": "3. Conductas\\Nimpulsivas:",
                "children": [
                  {
                    "text": "• Conducción temeraria",
                    "children": []
                  },
                  {
                    "text": "• Hurtos",
                    "children": []
                  },
                  {
                    "text": "• Compras/ventas irracionales",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "PREVALENCIA\\NSEGÚN NDD (44)",
            "children": [
              {
                "text": "• bvFTD: 42.3%",
                "children": []
              },
              {
                "text": "• AD: 30.7%",
                "children": []
              },
              {
                "text": "• DLB: 26.3%",
                "children": []
              },
              {
                "text": "• PD: 22.3%",
                "children": []
              }
            ]
          },
          {
            "text": "ASOCIACIONES\\NESPECÍFICAS",
            "children": [
              {
                "text": "• bvFTD + esclerosis lateral amiotrófica (80)",
                "children": []
              },
              {
                "text": "• bvFTD variante tau: 80-100% (81)",
                "children": []
              },
              {
                "text": "• HD: irritabilidad + impulsividad (82)",
                "children": []
              },
              {
                "text": "• TES:\\Ndesregulación\\Nneuroconductual:",
                "children": [
                  {
                    "text": "→ explosiones ira",
                    "children": []
                  },
                  {
                    "text": "→ conducta impulsiva",
                    "children": []
                  },
                  {
                    "text": "→ labilidad afectiva (24)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "NEUROBIOLOGÍA",
            "children": [
              {
                "text": "• Base anatómica común: disfunción orbitofrontal (83)",
                "children": []
              }
            ]
          },
          {
            "text": "TRATAMIENTO (84)",
            "children": [
              {
                "text": "1. Sin fármacos aprobados",
                "children": []
              },
              {
                "text": "2. Principales grupos\\Nfarmacológicos:",
                "children": [
                  {
                    "text": "• ISRS",
                    "children": []
                  },
                  {
                    "text": "• Antipsicóticos atípicos",
                    "children": []
                  },
                  {
                    "text": "• Antiepilépticos/estabilizadores ánimo",
                    "children": []
                  }
                ]
              },
              {
                "text": "3. Otros:",
                "children": [
                  {
                    "text": "• Estimulantes: ↓ desinhibición bvFTD",
                    "children": []
                  },
                  {
                    "text": "• Dextrometorfano\\N+ quinidina:",
                    "children": [
                      {
                        "text": "→ aprobado afecto pseudobulbar",
                        "children": []
                      },
                      {
                        "text": "→ potencial efecto desinhibición (85)",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "AVANCES Y DESAFÍOS\\NTRATAMIENTO NPS EN NDD",
        "children": []
      },
      {
        "text": "PROGRESO\\NRECIENTE",
        "children": [
          {
            "text": "1. Fármacos aprobados",
            "children": [
              {
                "text": "• Pimavanserin: psicosis PD",
                "children": []
              },
              {
                "text": "• Brexpiprazol: agitación AD",
                "children": []
              },
              {
                "text": "→ establecen precedentes regulatorios",
                "children": []
              },
              {
                "text": "→ demuestran diseños ensayos exitosos",
                "children": []
              },
              {
                "text": "→ validan medidas resultados (38,86)",
                "children": []
              }
            ]
          },
          {
            "text": "2. Limitaciones\\Nensayos clínicos",
            "children": [
              {
                "text": "• Baja inclusión grupos\\Nsubrepresentados:",
                "children": [
                  {
                    "text": "→ étnicos",
                    "children": []
                  },
                  {
                    "text": "→ raciales",
                    "children": []
                  },
                  {
                    "text": "→ geográficos",
                    "children": []
                  },
                  {
                    "text": "→ género",
                    "children": []
                  },
                  {
                    "text": "→ socioeconómicos (87)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "3. Terapias modificadoras\\Nenfermedad",
            "children": [
              {
                "text": "• AD: ↓30% progresión",
                "children": []
              },
              {
                "text": "• Potencial ↓ NPS (evidencia aducanumab) (88,89)",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "DESAFÍOS ACTUALES",
        "children": [
          {
            "text": "1. Tratamientos\\Ndisponibles:",
            "children": [
              {
                "text": "• Advertencias caja negra limitantes",
                "children": []
              },
              {
                "text": "• Inicio acción lento",
                "children": []
              },
              {
                "text": "• Remisión completa rara",
                "children": []
              },
              {
                "text": "• Magnitud mejoría subóptima",
                "children": []
              }
            ]
          },
          {
            "text": "2. Necesidad\\Nmejoras:",
            "children": [
              {
                "text": "• Farmacocinética",
                "children": []
              },
              {
                "text": "• Farmacodinámica",
                "children": []
              },
              {
                "text": "• Seguridad",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "AVANCES\\NDIAGNÓSTICOS",
        "children": [
          {
            "text": "1. Criterios investigación\\Ndisponibles:",
            "children": [
              {
                "text": "• Psicosis",
                "children": []
              },
              {
                "text": "• Agitación",
                "children": []
              },
              {
                "text": "• Apatía",
                "children": []
              },
              {
                "text": "• Depresión",
                "children": []
              },
              {
                "text": "• Desinhibición (21-23)",
                "children": []
              }
            ]
          },
          {
            "text": "2. Inclusión síndromes\\Npsiquiátricos criterios NDD:",
            "children": [
              {
                "text": "• AD",
                "children": []
              },
              {
                "text": "• FTD",
                "children": []
              },
              {
                "text": "• PSP",
                "children": []
              },
              {
                "text": "• Degeneración corticobasal",
                "children": []
              },
              {
                "text": "• DLB",
                "children": []
              },
              {
                "text": "• TES",
                "children": []
              },
              {
                "text": "• HD (2)",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "PERSPECTIVAS\\NFUTURAS",
        "children": [
          {
            "text": "1. Mejor comprensión:",
            "children": [
              {
                "text": "• Patobiología NDD",
                "children": []
              },
              {
                "text": "• Fisiopatología NPS",
                "children": []
              }
            ]
          },
          {
            "text": "2. Avances:",
            "children": [
              {
                "text": "• Neuroimagen estructural/funcional",
                "children": []
              },
              {
                "text": "• Estudios genéticos",
                "children": []
              },
              {
                "text": "• Biomarcadores",
                "children": []
              },
              {
                "text": "• Farmacogenómica",
                "children": []
              },
              {
                "text": "• Diseño/análisis ensayos",
                "children": []
              }
            ]
          },
          {
            "text": "3. Práctica clínica:",
            "children": [
              {
                "text": "• Prescripción mayormente off-label",
                "children": []
              },
              {
                "text": "• Base: observaciones + ensayos + guías expertos",
                "children": []
              },
              {
                "text": "• Desarrollo nuevas terapias en curso",
                "children": []
              }
            ]
          }
        ]
      }
    ]
  },
  "related_maps": [
    {
      "id": "map_1689",
      "title": "SPRINTT (2021)\\NSarcopenia and Physical\\NFragility in Older People:\\NMulti-component Treatment\\N\\n⭐ Ejercicio + nutrición reduce\\ndiscapacidad en fragilidad física\\ncon sarcopenia"
    },
    {
      "id": "map_1688",
      "title": "CLARITY-AD (2022)\\NLecanemab in Early Alzheimers Disease\\N\\nLecanemab reduce deterioro cognitivo 27%\\nen EA temprana con amiloide confirmado\\nPrimer anti-amiloide con beneficio clinico claro"
    },
    {
      "id": "map_1805",
      "title": "Deterioro Cognitivo Vascular (DCV)\\Ny Demencia Vascular"
    },
    {
      "id": "map_1107",
      "title": "Deterioro Cognitivo Vascular (DCV) y Demencia Vascular"
    },
    {
      "id": "map_1054",
      "title": "Evaluación de la Demencia y el Deterioro Cognitivo  UTD 2025"
    }
  ],
  "source_file": "JAMA 2024 | SÍNDROMES NEUROPSIQUIÁTRICOS (NPS) EN TRASTORNOS NEURODEGENERATIVOS (NDD)-2024.smmx",
  "created": "2026-02-07T15:43:03.596990"
}